2024-06 |
Dosimetric Comparison of CPAP and DIBH for Left-sided Breast Cancer Radiation Therapy |
Advances in Radiation Oncology
|
2024-03 |
Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy |
Yonsei Medical Journal
|
2024-02 |
Assessment of deep learning-based auto-contouring on interobserver consistency in target volume and organs-at-risk delineation for breast cancer: Implications for RTQA program in a multi-institutional study |
Breast
|
2024-01 |
Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma |
Cancer Research and Treatment
|
2023-12 |
Risk of on-treatment lymphopenia is associated with treatment outcome and efficacy of consolidation immunotherapy in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy |
Radiotherapy and Oncology
|
2023-09 |
Prognostic impact of radiotherapy-induced-lymphopenia in patients treated with breast-conservative surgery |
Scientific Reports
|
2023-05 |
Neural network based ensemble model to predict radiation induced lymphopenia after concurrent chemo-radiotherapy for non-small cell lung cancer from two institutions |
NEOPLASIA
|
2023-05 |
Radiation dose-event relationship after intraoperative radiotherapy as a boost in patients with breast cancer |
FRONTIERS IN ONCOLOGY
|
2022-05 |
Intraoperative Radiotherapy for Resectable Pancreatic Cancer Using a Low-Energy X-Ray Source: Postoperative Complications and Early Outcomes |
YONSEI MEDICAL JOURNAL
|
2022-05 |
Association of neutrophil-to-lymphocyte ratio, radiotherapy fractionation/technique, and risk of development of distant metastasis among patients with locally advanced rectal cancer |
RADIATION ONCOLOGY
|
2022-04 |
Validation of a nomogram for predicting the risk of lymphedema following contemporary treatment for breast cancer: a large multi-institutional study (KROG 20-05) |
Breast Cancer Research and Treatment
|
2022-03 |
Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy |
RADIOTHERAPY AND ONCOLOGY
|